Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®)
- 1 January 2004
- journal article
- review article
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 8, S31-S40
- https://doi.org/10.1016/j.ejon.2004.06.007
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancerBritish Journal of Cancer, 2003
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorinAnnals of Oncology, 2002
- Incidence and Severity of Hand–Foot Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-Institution ExperienceCancer Investigation, 2002
- Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal CancerJournal of Clinical Oncology, 2000
- Expression and localization of thymidine phosphorylase/platelet‐derived endothelial cell growth factor in skin and cutaneous tumorsJournal of Cutaneous Pathology, 1999
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Treatment of cytarabine acral erythema with corticosteroidsJournal of the American Academy of Dermatology, 1991
- Chemotherapy-induced acral erythemaJournal of the American Academy of Dermatology, 1991
- Peculiar Acral Erythema Secondary to High-Dose Chemotherapy for Acute Myelogenous LeukemiaAnnals of Internal Medicine, 1982